Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications

详细信息    查看全文

• 作者：Jonathan K. Dozier ; Santoshkumar L. Khatwani ; James W. Wollack ; Yen-Chih Wang ; Claudia Schmidt-Dannert ; Mark D. Distefano
• 刊名：Bioconjugate Chemistry
• 出版年：2014
• 出版时间：July 16, 2014
• 年：2014
• 卷：25
• 期：7
• 页码：1203-1212
• 全文大小：402K
• ISSN：1520-4812

文摘

Creating covalent protein conjugates is an active area of research due to the wide range of uses for protein conjugates spanning everything from biological studies to protein therapeutics. Protein Farnesyltransferase (PFTase) has been used for the creation of site-specific protein conjugates, and a number of PFTase substrates have been developed to facilitate that work. PFTase is an effective catalyst for protein modification because it transfers Farnesyl diphosphate (FPP) analogues to protein substrates on a cysteine four residues from the C-terminus. While much work has been done to synthesize various FPP analogues, there are few reports investigating how mutations in PFTase alter the kinetics with these unnatural analogues. Herein we examined how different mutations within the PFTase active site alter the kinetics of the PFTase reaction with a series of large FPP analogues. We found that mutating either a single tryptophan or tyrosine residue to alanine results in greatly improved catalytic parameters, particularly in k_cat. Mutation of tryptophan 102尾 to alanine caused a 4-fold increase in k_cat and a 10-fold decrease in K_M for a benzaldehyde-containing FPP analogue resulting in an overall 40-fold increase in catalytic efficiency. Similarly, mutation of tyrosine 205尾 to alanine caused a 25-fold increase in k_cat and a 10-fold decrease in K_M for a coumarin-containing analogue leading to a 300-fold increase in catalytic efficiency. Smaller but significant changes in catalytic parameters were also obtained for cyclo-octene- and NBD-containing FPP analogues. The latter compound was used to create a fluorescently labeled form of Ciliary Neurotrophic Factor (CNTF), a protein of therapeutic importance. Additionally, computational modeling was performed to study how the large non-natural isoprenoid analogues can fit into the active sites enlarged via mutagenesis. Overall, these results demonstrate that PFTase can be improved via mutagenesis in ways that will be useful for protein engineering and the creation of site-specific protein conjugates.